Latest Insider Transactions at Allogene Therapeutics, Inc. (ALLO)
This section provides a real-time view of insider transactions for Allogene Therapeutics, Inc. (ALLO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Allogene Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Allogene Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 06
2020
|
Alison Moore Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35,264
+17.92%
|
$70,528
$2.27 P/Share
|
|
Oct 01
2020
|
Rafael Amado EVP of R&D |
SELL
Open market or private sale
|
Direct |
9,752
-7.07%
|
$351,072
$36.37 P/Share
|
|
Oct 01
2020
|
Veer Bhavnagri General Counsel |
SELL
Open market or private sale
|
Direct |
25,000
-2.24%
|
$900,000
$36.99 P/Share
|
|
Oct 01
2020
|
Veer Bhavnagri General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+6.19%
|
$50,000
$2.27 P/Share
|
|
Oct 15
2018
|
Pfizer Inc > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
55,556
+0.25%
|
$1,000,008
$18.0 P/Share
|
|
Oct 15
2018
|
Pfizer Inc > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
21,976,484
+50.0%
|
-
|